ReCode Therapeutics
ReCode Therapeutics is a biotechnology company focused on developing treatments for genetically defined diseases lacking existing options, such as primary ciliary dyskinesia and cystic fibrosis, using its SORT LNP platform for targeted genetic medicine delivery.
Therapeutics for Genetically Defined Diseases
ReCode Therapeutics develops innovative therapeutics for genetically defined diseases that currently lack existing treatment options. The company's focus includes primary ciliary dyskinesia and cystic fibrosis. By targeting these specific diseases, ReCode aims to address significant unmet medical needs and improve patient outcomes through advanced genetic medicines.
SORT LNP Platform
ReCode Therapeutics utilizes the SORT LNP platform, a pioneering modular technology designed for the targeted delivery of genetic medicines. This first-in-class technology enables precise delivery to organs, tissues, and cells beyond the liver, setting a new standard in the field of genetic medicine delivery. The SORT LNP platform supports ReCode's commitment to developing effective therapies for rare and genetically defined diseases.
Pipeline of Rare Disease Therapeutics
ReCode Therapeutics offers a robust pipeline of rare disease therapeutics, focusing on optimizing mRNA and gene correction with the capability for repeated dosing. This innovative approach enhances the potential for effective and sustained treatment of rare genetic conditions, reaffirming ReCode's dedication to advancing the field of genetic medicine and providing new hopes for patients with limited treatment options.
Collaboration with the Cystic Fibrosis Foundation
ReCode Therapeutics collaborates with the Cystic Fibrosis Foundation to support preclinical research and early-stage clinical trials for cystic fibrosis therapies. This partnership underscores ReCode's commitment to developing effective treatments for cystic fibrosis, leveraging both organizations' expertise to accelerate the path from research to market, ultimately aiming to improve the lives of those affected by this genetic disorder.
Headquarters
ReCode Therapeutics is headquartered at 1140 O’Brien Drive, Menlo Park, CA 94025. Located in a region renowned for its biotech innovation, the headquarters serves as the central hub for ReCode's research, development, and operational activities. This strategic location supports collaboration with leading scientists and institutions in the biotech industry, further advancing ReCode's mission to develop transformative genetic medicines.